We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa.
- Authors
Zouboulis, Christos C.; Hansen, Hendrik; Caposiena Caro, Raffaele Dante; Damiani, Giovanni; Delorme, Isabelle; Pascual, José Carlos; Reguiai, Ziad; Trigoni, Anastasia; Vilarrasa, Eva; Alfageme Roldán, Fernando; Zouboulis, Christos C; Caposiena Caro, Raffaele Dante; Pascual, José Carlos; Alfageme Roldán, Fernando
- Abstract
<bold>Background: </bold>Adalimumab is the only approved compound for the treatment of adult patients with moderate-to-severe hidradenitis suppurativa (HS) who did not respond to a systemic classical treatment. Despite its significant short- and long-term efficacy, a percentage of patients do not respond sufficiently. Moreover, some primary responders experience a response loss with time.<bold>Objective: </bold>To analyse the effectiveness of adalimumab dose intensification in HS patients.<bold>Methods: </bold>A case series of adalimumab 80 mg/week subcutaneously (s.c.) compassionate use in patients with HS, who did not respond sufficiently or in primary responders with progressive response loss to the registered adalimumab dose of 40 mg/week s.c. Patients were collected and evaluated retrospectively. Patients' data were extracted from medical records.<bold>Results: </bold>The 14 patients collected were Caucasian with HS of Hurley stage II-III and moderate or severe International HS Severity Score System (IHS4) stage. Adalimumab dose intensification significantly improved IHS4 score, Pain Index, HS-Physician Global Assessment, pain, and Cardiff Dermatology Life Quality Index. Two young female patients with HS and Crohn's disease developed psoriatic lesions during the treatment with adalimumab 80 mg/week s.c.<bold>Conclusion: </bold>An enhanced level of effectiveness was assessed in the majority of the HS patients treated with adalimumab dose intensification (80 mg/week s.c.). Larger studies are required to evaluate this observation.
- Subjects
HIDRADENITIS suppurativa; CROHN'S disease; ADALIMUMAB
- Publication
Dermatology (10188665), 2020, Vol 236, Issue 1, p25
- ISSN
1018-8665
- Publication type
journal article
- DOI
10.1159/000503606